7TM Pharma’s Anti-Obesity Drug Completes Phase I/II Clinical Studies

7TM Pharma A/S has announced positive results from its clinical Phase I/II study with its lead compound TM30338, a dual Y2-Y4 receptor agonist developed for the treatment of obesity and related diseases. Both the primary and secondary objective of the study was met. Thus, the study demonstrated that the drug candidate is safe and well tolerated in man. Importantly, in obese human subjects once-a-day subcutaneous dosing of TM30338 inhibited food intake at a statistically significant level up to at least 9 hours after dosing.

Based on the promising Phase I/II data, a substantial Phase IIa clinical study with TM30338 is currently being planned. Furthermore, pre-clinical development of 7TM Pharma's next clinical candidate for the obesity indication, a selective Y4 receptor agonist peptide, was initiated last year and the company expects to initiate phase I/II studies on TM30339 in 2006. Both of these programs, which are within the core therapeutic area of 7TM Pharma -i.e. obesity and related metabolic diseases -, are still fully owned by the company.

Obesity and the metabolic syndrome are considered a major health problem and challenge to the developed world. Obesity significantly increases the risk of, for example, cardiovascular diseases and diabetes type II and resulting in enormous health care expenditure. There are more than 300 million clinically obese people worldwide with a BMI above 30 and the number is growing rapidly. Despite this, current obesity treatment is restricted to a few drugs with limited efficacy and notable side effects and there is an urgent need for new and improved treatment possibilities.

For further information please contact:

Mette Kirstine Agger,

CEO

Tel: +45 39 25 77 77

Email: mka@7tm.com

Or visit: www.7tm.com